Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?

Tigen K., Cevik C.

CURRENT PHARMACEUTICAL DESIGN, cilt.16, sa.26, ss.2866-2871, 2010 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 16 Sayı: 26
  • Basım Tarihi: 2010
  • Doi Numarası: 10.2174/138161210793176473
  • Dergi Adı: CURRENT PHARMACEUTICAL DESIGN
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2866-2871
  • Anahtar Kelimeler: Dilated Cardiomyopathy, Beta-blocker Therapy, CHRONIC HEART-FAILURE, OBSTRUCTIVE PULMONARY-DISEASE, LEFT-VENTRICULAR DYSFUNCTION, CARDIOVASCULAR DRUG-THERAPY, LONG-TERM TREATMENT, ELDERLY-PATIENTS, ATRIAL-FIBRILLATION, ADRENERGIC-BLOCKADE, DOUBLE-BLIND, RETROSPECTIVE ANALYSIS
  • Marmara Üniversitesi Adresli: Hayır

Özet

Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.